Zacks Investment Research upgraded shares of OpGen (NASDAQ:OPGN) from a hold rating to a buy rating in a research report released on Thursday morning. They currently have $1.25 target price on the medical research company’s stock.

According to Zacks, “OpGen, Inc. is a microbial genetics analysis company. The Company offers optical mapping services for analysis of microbial, yeast and fungal genomic architecture. OpGen, Inc. headquartered in Gaithersburg, Maryland. “

OPGN has been the subject of several other research reports. HC Wainwright set a $6.00 price objective on OpGen and gave the company a buy rating in a research report on Wednesday, December 5th. Alliance Global Partners assumed coverage on OpGen in a research report on Friday, March 1st. They issued a buy rating and a $2.30 price objective for the company.

Shares of OPGN stock opened at $0.86 on Thursday. The company has a quick ratio of 1.20, a current ratio of 1.32 and a debt-to-equity ratio of 0.33. OpGen has a fifty-two week low of $0.76 and a fifty-two week high of $2.90. The company has a market capitalization of $7.44 million, a price-to-earnings ratio of -0.39 and a beta of 1.14.

OpGen (NASDAQ:OPGN) last announced its quarterly earnings data on Tuesday, February 26th. The medical research company reported ($0.47) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.38) by ($0.09). OpGen had a negative net margin of 453.73% and a negative return on equity of 232.38%. On average, equities analysts predict that OpGen will post -0.93 EPS for the current year.

An institutional investor recently bought a new position in OpGen stock. Bank of New York Mellon Corp acquired a new stake in OpGen Inc (NASDAQ:OPGN) in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 20,688 shares of the medical research company’s stock, valued at approximately $27,000. Bank of New York Mellon Corp owned about 0.24% of OpGen as of its most recent filing with the Securities & Exchange Commission. 5.47% of the stock is currently owned by institutional investors and hedge funds.

OpGen Company Profile

OpGen, Inc, a precision medicine company, engages in developing molecular information products and services to combat infectious diseases in the healthcare industry worldwide. The company utilizes molecular diagnostics and bioinformatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections, enhance patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms.

Recommended Story: What is the return on assets (ROA) ratio?

Get a free copy of the Zacks research report on OpGen (OPGN)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with's FREE daily email newsletter.